PI Pharma Insight

BNF presentation directory

Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.

Reset

Active filters

  • Chemical substance: Combined ethinylestradiol 35mcg
Presentation Product Chemical substance Chapter Items dispensed
Lizinna 250microgram/35microgram tablets
0703010G0BGAAAC
Lizinna Combined ethinylestradiol 35mcg Obstetrics, Gynaecology and Urinary-Tract Disorders 11,070
Cilique 250microgram/35microgram tablets
0703010G0BHAAAC
Cilique Combined ethinylestradiol 35mcg Obstetrics, Gynaecology and Urinary-Tract Disorders 10,861
Ethinylestradiol 35microgram / Norgestimate 250microgram tab
0703010G0AAACAC
Combined ethinylestradiol 35mcg Combined ethinylestradiol 35mcg Obstetrics, Gynaecology and Urinary-Tract Disorders 8,166
Brevinor 500microgram/35microgram tablets
0703010G0BCAAAA
Brevinor Combined ethinylestradiol 35mcg Obstetrics, Gynaecology and Urinary-Tract Disorders 3,497
Norimin 1mg/35microgram tablets
0703010G0BDAAAB
Norimin Combined ethinylestradiol 35mcg Obstetrics, Gynaecology and Urinary-Tract Disorders 851
Ethinylestradiol 35microg / Norethisterone 500microg tab
0703010G0AAAAAA
Combined ethinylestradiol 35mcg Combined ethinylestradiol 35mcg Obstetrics, Gynaecology and Urinary-Tract Disorders 733
Ethinylestradiol 35microgram / Norethisterone 1mg tablets
0703010G0AAABAB
Combined ethinylestradiol 35mcg Combined ethinylestradiol 35mcg Obstetrics, Gynaecology and Urinary-Tract Disorders 189
Cilest 35microgram/250microgram tablets
0703010G0BFAAAC
Cilest Combined ethinylestradiol 35mcg Obstetrics, Gynaecology and Urinary-Tract Disorders 47
Ovysmen 500microgram/35microgram tablets
0703010G0BBAAAA
Ovysmen Combined ethinylestradiol 35mcg Obstetrics, Gynaecology and Urinary-Tract Disorders No data available

Why monitor BNF codes?

Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.

Track cost pressure

Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.

Understand demand drivers

Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.